Destiny Pharma announces update on clinical programme for lead drug candidate XF-73

April 12, 2018
Destiny Pharma plc

Brighton, United Kingdom - 12 April 2018 - Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel anti-microbial drugs, which address the global problem of anti-microbial resistance (AMR), today announces an update on the scope and timing of the XF-73 (exeporfinium chloride) Phase 1 and Phase 2b clinical trial programmes following discussions with the US Food and Drug Administration (FDA). This process is in line with the Company's strategy set out at the time of the placing and admission to AIM and the current status is summarised below (...).

Press Release available here: